The KRAS mutation is not responsible for all cases of resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new predictive and prognostic factors are actively being sought.

Inno, A., Di Salvatore, M., Cenci, T., Martini, M., Orlandi, A., Strippoli, A., Ferrara, A. M., Bagala', C., Cassano, A., Larocca, L. M., Barone, C. A., Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?, <<CLINICAL COLORECTAL CANCER>>, 2011; 10 (4): 325-332. [doi:10.1016/j.clcc.2011.03.028] [http://hdl.handle.net/10807/25735]

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Inno;Alessandro; Di Salvatore;Mariantonietta; Cenci;Tonia; Martini;Maurizio; Orlandi;Armando; Strippoli;Antonia; Ferrara;Anna Maria; Bagala';Cinzia; Cassano;Alessandra; Larocca;Luigi Maria; Barone
2011

Abstract

The KRAS mutation is not responsible for all cases of resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new predictive and prognostic factors are actively being sought.
Inglese
Inno, A., Di Salvatore, M., Cenci, T., Martini, M., Orlandi, A., Strippoli, A., Ferrara, A. M., Bagala', C., Cassano, A., Larocca, L. M., Barone, C. A., Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?, <<CLINICAL COLORECTAL CANCER>>, 2011; 10 (4): 325-332. [doi:10.1016/j.clcc.2011.03.028] [http://hdl.handle.net/10807/25735]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/25735
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact